Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients

Pyrotinib Plus Trastuzumab and Chemotherapy in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05839288

Enrollment

161

Registered

2023-05-03

Start date

2022-11-01

Completion date

2023-04-01

Last updated

2023-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Pyrotinib

Brief summary

To evaluate the patterns and treatment outcomes of pyrotinib plus trastuzumab and chemotherapy in the real world.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* woman, age \> 18 years old * diagnosed with HER2 +Metastatic Breast Cancer * received pyrotinib plus trastuzumab and chemotherapy for at least one cycle, starting from 2018.07-2022.09 * available medical history

Exclusion criteria

* medical history was incomplete

Design outcomes

Primary

Measure	Time frame	Description
progression-free survival (PFS)	6 weeks	Progression free survival

Secondary

Measure	Time frame	Description
Adverse events	6 weeks	Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)

Countries

China

Outcome results